India Drug Industry Expects No Additional Budget Benefits
This article was originally published in PharmAsia News
Executive Summary
India's pharmaceutical industry does not expect any particular benefit from the Union Budget 2008 being developed by a government facing upcoming national elections. The government has announced several populist health-care measures to benefit the public at large, including some favored by the Pharmaceutical and Biotechnology Industry. But the benefits are not expected to be as high as suggested. Benefits include weighted research-and-development deductions, reduced custom duty on certain drugs and reduction of excise duties on all drugs. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.